Insulin-like growth factor (IGF)-I levels in postmenopausal women receiving tibolone.
Hopkins
K D
KD
Department of Obstetrics and Gynaecology, Guy's Hospital, London, United Kingdom.
Parker
J R
JR
Lehmann
E D
ED
Rymer
J
J
Holly
J M
JM
Fogelman
I
I
Cwyfan-Hughes
S
S
Teale
J D
JD
Gosling
R G
RG
D045930:Anabolic Agents; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D017698:Postmenopause / Q000097:blood*
D045930:Anabolic Agents; D009652:Norpregnenes; D007334:Insulin-Like Growth Factor I; C027385:tibolone